Results 1 to 10 of about 1,127,435 (235)

Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer [PDF]

The Korean Journal of Internal Medicine, 2020
Background/Aims We evaluated the efficacy of docetaxel and epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer and assessed the predictive factors for response to neoadjuvant chemotherapy and prognostic factors related to relapse ...
Hye Sung Won, Yong Seok Kim, Jeong Soo Kim, Eun Deok Chang, Sae Jung Na, In Yong Whang, Dong Soo Lee   +6 more
doaj   +1 more source

Neoadjuvant therapy in patients with locally advanced colon cancer [PDF]

Waike lilun yu shijian, 2022
It is still unclear about neoadjuvant therapy in patients with locally advanced colon cancer (LACC). This review summarized neoadjuvant chemotherapy, neoadjuvant chemotherapy combined with targeted therapy and combined radio-chemotherapy for the patients
XU Zifeng, ZONG Yaping, LU Aiguo
doaj   +1 more source

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

New England Journal of Medicine, 2022
BACKGROUND Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non-small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens have shown promising clinical activity; however ...
P. Forde, J. Spicer, Shun Lu, M. Provencio, T. Mitsudomi, M. Awad, E. Felip, S. Broderick, J. Brahmer, S. Swanson, K. Kerr, Changli Wang, T. Ciuleanu, G. Saylors, F. Tanaka, H. Ito, Keke Chen, M. Liberman, E. Vokes, J. Taube, C. Dorange, Junliang Cai, J. Fiore, A. Jarkowski, D. Balli, M. Sausen, D. Pandya, C. Calvet, N. Girard   +28 more
semanticscholar   +1 more source

Body composition change during neoadjuvant chemotherapy for breast cancer

Frontiers in Oncology, 2022
BackgroundSarcopenia is receiving attention in oncology as a predictor of increased chemotherapy toxicities. Research into body composition change during neoadjuvant chemotherapy for breast cancer is both urgently needed and generally lacking. This study
Min Kyeong Jang, Seho Park, Chang Park, Ardith Z. Doorenbos, Ardith Z. Doorenbos, Jieon Go, Sue Kim   +6 more
doaj   +1 more source

Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer [PDF]

, 2012
In our previous work we showed that NGAL, a protein involved in the regulation of proliferation and differentiation, is overexpressed in human breast cancer (BC) and predicts poor prognosis.
Arnold, Norbert, Ataseven, Beyhan, Bauer, Maret, Darb-Esfahani, Silvia, Denkert, Carsten Michael, Hamann, Sigrid, Holzhausen, Hans-Jürgen, Jonat, Walter, Khandan, Fariba, Loibl, Sibylle, Mehta, Keyur, Minckwitz, Gunther von, Mundhenke, Christoph, Müller, Berit, Park, Hyerim, Schem, Christian, Thomssen, Christoph, Weimer, Joerg, Wenners, Antonia Sophie   +18 more
core   +11 more sources

Clinicopathological factors affecting the effect of neoadjuvant chemotherapy in patients with gastric cancer

World Journal of Surgical Oncology, 2021
Background Neoadjuvant chemotherapy is an important part of the comprehensive treatment of advanced gastric cancer (GC). The effect of neoadjuvant chemotherapy plays a key role in the prognosis of GC patients.
Lin Jiang, Zhiqiang Ma, Xin Ye, Weiming Kang, Jianchun Yu   +4 more
doaj   +1 more source

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

The Lancet Oncology, 2021
BACKGROUND Treatment of locally advanced rectal cancer with chemoradiotherapy, surgery, and adjuvant chemotherapy controls local disease, but distant metastases remain common.
T. Conroy, J. Bosset, P. Etienne, E. Rio, E. François, N. Mesgouez-Nebout, V. Vendrely, X. Artignan, O. Bouché, D. Gargot, V. Boige, N. Bonichon-Lamichhane, C. Louvet, C. Morand, C. de la Fouchardière, N. Lamfichekh, B. Juzyna, Claire Jouffroy-Zeller, E. Rullier, F. Marchal, S. Gourgou, F. Castan, C. Borg   +22 more
semanticscholar   +1 more source

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

Journal of Clinical Oncology, 2021
PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature on neoadjuvant therapy for breast cancer and provide recommended
L. Korde, M. Somerfield, L. Carey, J. Crews, N. Denduluri, E. Hwang, S. Khan, S. Loibl, E. Morris, Alejandra T. Perez, M. Regan, P. Spears, P. Sudheendra, W. Symmans, R. Yung, Brittany E. Harvey, D. Hershman   +16 more
semanticscholar   +1 more source

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Nature Medicine, 2023
The combination of neoadjuvant nivolumab, ipilimumab and chemotherapy showed promising efficacy in patients with resectable non-small cell lung cancer, with higher tumor immune cell infiltration and tertiary lymphoid structures after treatment compared ...
T. Cascone, C. Leung, A. Weissferdt, A. Pataer, B. Carter, M. Godoy, Hope A. Feldman, W. William, Y. Xi, Sreyashi Basu, J. Sun, S. Yadav, F. R. Rojas Alvarez, Younghee Lee, Aditya K Mishra, Lili Chen, M. Pradhan, Haiping Guo, Ansam Sinjab, N. Zhou, M. Negrão, X. Le, C. Gay, A. Tsao, L. Byers, M. Altan, B. Glisson, F. Fossella, Y. Elamin, G. Blumenschein, Jianjun Zhang, F. Skoulidis, Jia Wu, R. Mehran, D. Rice, G. Walsh, W. Hofstetter, R. Rajaram, M. Antonoff, J. Fujimoto, L. Solis, E. Parra, C. Haymaker, I. Wistuba, S. Swisher, A. Vaporciyan, Heather Y. Lin, Jing Wang, D. Gibbons, J. Jack Lee, N. Ajami, J. Wargo, J. Allison, Padmanee Sharma, H. Kadara, J. Heymach, B. Sepesi   +56 more
semanticscholar   +1 more source

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

The Lancet Oncology, 2021
Summary Background Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy.
C. Yau, M. Osdoit, M. V. D. van der Noordaa, S. Shad, Jane Wei, Diane de Croze, A. Hamy, M. Laé, F. Reyal, G. Sonke, T. Steenbruggen, M. van Seijen, J. Wesseling, Miguel Martín, M. del Monte-Millán, S. López-Tarruella, J. Boughey, M. Goetz, T. Hoskin, R. Gould, V. Valero, S. Edge, J. Abraham, J. Bartlett, C. Caldas, J. Dunn, H. Earl, L. Hayward, L. Hiller, E. Provenzano, S. Sammut, J. Thomas, D. Cameron, A. Graham, P. Hall, L. Mackintosh, Fang-tian Fan, A. Godwin, Kelsey Schwensen, Priyanka Sharma, A. DeMichele, K. Cole, L. Pusztai, Mi-Ok Kim, L. J. van ’t Veer, L. Esserman, W. Symmans   +46 more
semanticscholar   +1 more source